All In Biotech

Drug Trial Radar · NCT05128409

Phase I of XKH001Injection in Healthy Adults

A Randomized, Double-Blind, Placebo-Controlled, Phase I Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of XKH001Injection in Healthy Adults

Last checked: Nov 19, 2026Latest source record: Apr 12, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

35

Planned (sponsor's estimate)

Start

Mar 7, 2023

Primary completion

Oct 1, 2024

Study completion Dec 1, 2024

Sponsor

Sponsor type
Industry
First posted
Nov 22, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Triple (care provider, investigator, outcomes assessor)
Primary purpose
Health services research
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

XKH001is a recombinant humanized monoclonal IgG1 antibody for subcutaneous injection. XKH001 specifically blocks interleukin-25 from binding to its receptors. To evaluate the safety, tolerability, pharmacokinetics (PK) of single ascending doses of XKH001 injection following subcutaneous administration

Conditions

  • Healthy Adults

Interventions

  • XKH001 InjectionDrug

    0.5mg/kg: 3Subjects,1Sentinel Participants 1.67mg/kg: 6Subjects, ,1Sentinel Participants 3.34mg/kg: 6Subjects,1Sentinel Participants 5.0mg/kg: 6Subjects, ,1Sentinel Participants 10.0mg/kg: 6Subjects,1Sentinel Participants

  • XKH001Placebo InjectionDrug

    1.67mg/kg: 2Subjects,1Sentinel Participants 3.34mg/kg: 2Subjects,1Sentinel Participants 5.0mg/kg: 2Subjects,1Sentinel Participants 10.0mg/kg: 2Subjects, 1Sentinel Participants

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of adverse events (AEs)Time frame: from admission to discharge, up to 8 weeks
  2. Incidence of serious adverse events (SAEs)Time frame: from admission to discharge, up to 8 weeks
  3. AEs leading to termination of dose escalationTime frame: from admission to discharge, up to 8 weeks
  4. Reported values and changes from baseline in clinical laboratory investigations (hematology)Time frame: from admission to discharge, up to 8 weeks
  5. Reported values and changes from baseline in clinical laboratory investigations (serum chemistry)Time frame: from admission to discharge, up to 8 weeks
  6. Reported values and changes from baseline in clinical laboratory investigations ( urinalysis)Time frame: from admission to discharge, up to 8 weeks
  7. Reported values and changes from baseline in clinical laboratory investigations ( coagulation)Time frame: from admission to discharge, up to 8 weeks
  8. vital signs (respiratory rate)Time frame: from admission to discharge, up to 8 weeks
  9. vital signs (body temperature)Time frame: from admission to discharge, up to 8 weeks
  10. vital signs (supine blood pressure)Time frame: from admission to discharge, up to 8 weeks
  11. vital signs (pulse)Time frame: from admission to discharge, up to 8 weeks
  12. 12-lead electrocardiograms (ECGs)Time frame: from admission to discharge, up to 8 weeks
  13. maximum serum concentration of XKH001Time frame: from admission to discharge, up to 8 weeks
  14. time to reach maximum serum concentration of XKH001Time frame: from admission to discharge, up to 8 weeks
  15. area under the serum concentration versus time curve from time zero to time t of XKH001Time frame: from admission to discharge, up to 8 weeks
  16. systemic clearance of XKH001Time frame: from admission to discharge, up to 8 weeks
  17. volume of distribution of XKH001Time frame: from admission to discharge, up to 8 weeks
  18. terminal half-life of XKH001Time frame: from admission to discharge, up to 8 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Hospital of Jilin University Phase I Clinical Research Center

    Changchun, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.